Biotechnology · Paris, France · Founded 2014 · Privately Held (backing)
Developer of DNA printer technology designed to print synthetic nucleic acids for genomics and molecular biology applications. DNA Script is based in Paris, France and was founded in 2014. It was valued at $660 million at its later-stage round in Jan 2022, the last priced event on record. It has raised $299 million across 1 recorded round; the latest was a $192 million Series C in Jan 2022.
PMV mark · valuation
$659.7M
Oct 2026
Priced at
its later-stage round
Jan 2022
Total raised
$298.7M
Last round
Later Stage VC (Series C)
Jan 2022
No prints on record
No secondary trades in DNA Script shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of DNA Script with a free account
·The complete investor list: 34 names
·Watch DNA Script: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of DNA Script stock.
